Progyny (NASDAQ:PGNY - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to post earnings of $0.45 per share and revenue of $307.86 million for the quarter.
Progyny Trading Down 1.5 %
NASDAQ:PGNY traded down $0.35 during trading hours on Tuesday, hitting $23.06. The company had a trading volume of 191,020 shares, compared to its average volume of 1,738,430. Progyny has a 1 year low of $13.39 and a 1 year high of $33.84. The company has a market cap of $1.98 billion, a P/E ratio of 39.72, a P/E/G ratio of 2.39 and a beta of 1.37. The company has a 50-day moving average of $21.90 and a 200 day moving average of $19.37.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on PGNY shares. JPMorgan Chase & Co. raised their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a report on Monday, March 31st. Bank of America upped their price objective on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Finally, Canaccord Genuity Group raised their target price on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $23.64.
Check Out Our Latest Research Report on Progyny
About Progyny
(
Get Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Stories
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
